Investor Relations

COO Message

At StemRIM, since our foundation, we have pursued development of “regeneration-inducing medicine”, a groundbreaking type of new medicine. Many years of research have revealed that regeneration-inducing medicine draws out the human body’s innate ability to repair tissue to its maximum potential, promoting tissue regeneration and healing in body tissues that have lost their function by being damaged due to injury or disease. Unlike conventional regenerative medicine or cell therapy, “regeneration-inducing medicine” is used by administering a substance (the medicine), removing the restrictions associated with regenerative therapy/cell therapy such as invasiveness, quality control and cost. It also has the potential to become a new type of regenerative therapy covering a wide range of indications.

We aim to be a biotechnology company that takes on new challenges, fostering free and broad-ranging research by life scientists, in order to continue to provide innovative new medicines to patients suffering from intractable diseases across the world. We will continue to pursue these challenges to achieve a future where regeneration-inducing medicine created in Japan can bring smiles to the faces of people across the world.

We offer our sincere thanks to all our shareholders and investors for their kind support of our company thus far. As we pursue our goal of realizing the potential of “regeneration-inducing medicine”, we hope to continue to receive your instruction and encouragement in the future.

COO Masatsune Okajima